Aarvis Novo Private Limited

Pharmaceutical company manufacturing and exporting medicines and chemicals.

2018 | Raigarh, Maharashtra (India) | Inactive
Last Updated: January 30, 2025

Aarvis Novo Profile

Key Indicators

  • Authorised Capital ₹ 0.10 M
  • Paid Up Capital ₹ 0.10 M
  • Company Age 6 Year, 11 Months
  • Last Filing with ROC 31 Mar 2022
  • Revenue Growth %
  • Profit Growth 34.93%
  • Ebitda 57.57%
  • Net Worth -22.19%
  • Total Assets -6.57%

About Aarvis Novo

Aarvis Novo Private Limited (ANPL) is Strike Off company established on 20 Feb 2018 with its office registered at Raigarh, Maharashtra, India and has been running since 6 Year, 11 Months with a paid up capital of 0.10 M. According to MCA records, 2 Directors are linked to this company as of 30 Jan 2025.

Company Details

  • Location

    Raigarh, Maharashtra, India

  • Telephone

    +91-XXXXXXXXXX

  • Email Address

  • Website

    -

  • Social Media
    -

Corporate Identity Details

  • CIN/LLPIN

    U74999MH2018PTC305285

  • Company No.

    305285

  • Company Classification

    Private Limited Indian Non-Government Company

  • Incorporation Date

    20 Feb 2018

  • Date of AGM

    30 Sep 2022

  • Date of Balance Sheet

    31 Mar 2022

  • Listing Status

    Unlisted

  • ROC Code

    Roc Mumbai

Industry

Pharma

Who are the key members and board of directors at Aarvis Novo?

Board Members (2)

Name Designation Appointment Date Status
Rajendra Verma Country flag representing In Director 20-Feb-2018 Current
Ashok Kumar Country flag representing In Director 20-Feb-2018 Current

Financial Performance of Aarvis Novo.

Aarvis Novo Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 34.93% increase in profit. The company's net worth observed a substantial decline by a decrease of 22.19%.

Graph illustrating revenue growth over time
Graph showing profit and loss trends over time
  • Key Matrics
  • Balance Sheet
  • Profit and Loss
  • Cash Flow
  • Ratios
Metrics
(FY 2023) YOY Growth
(FY 2022) (FY 2021) (FY 2020) (FY 2019)
Total Revenue
Revenue from Operations
Total Assets
-6.57%
Profit or Loss
34.93%
Net Worth
-22.19%
EBITDA
57.57%

What is the Ownership and Shareholding Structure of Aarvis Novo?

Unlock access to Aarvis Novo's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.

Shareholding Indicator graph

Charges (Loans)

Placeholder for charges-related data

There are no open charges registered against the company as per our records.

How Many Employees Work at Aarvis Novo?

Unlock and access historical data on people associated with Aarvis Novo, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.

Graph showing employee growth trends

Deals i

Graph showing company valuation over time

Gain comprehensive insights into the Deals and Valuation data of Aarvis Novo, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aarvis Novo's trajectory.

Rating

Graph displaying rating trends over time

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts

Alert Indicator

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Latest Updates, News, and FAQs on Aarvis Novo

Recent activity within the organization

  • Annual General Meeting

    Aarvis Novo Private Limited last Annual general meeting of members was held on 30 Sep 2022 as per latest MCA records.

    30 Sep 2022

  • Balance Sheet

    Aarvis Novo Private Limited has filed its annual Financial statements for the year ended 31 Mar 2022 with Roc Mumbai.

    31 Mar 2022

  • Director Appointment

    Rajendra Kumar Verma was appointed as a Director was appointed as a Director on 20 Feb 2018 & has been associated with this company since 6 years 11 months .

    20 Feb 2018

  • Director Appointment

    Ashok Ramnandan Kumar was appointed as a Director was appointed as a Director on 20 Feb 2018 & has been associated with this company since 6 years 11 months .

    20 Feb 2018

  • Company Incorporation

    Aarvis Novo Private Limited was registered on 20 Feb 2018 with Roc Mumbai & aged 6 years 11 months as per MCA records.

    20 Feb 2018

Frequently asked questions

  • Aarvis Novo Private Limited was incorporated on 20 Feb 2018.

  • The authorized share capital of Aarvis Novo Private Limited is ₹ 0.10 M and paid-up capital is ₹ 0.10 M.

  • Currently 2 directors are associated with Aarvis Novo Private Limited.

    • Rajendra Kumar Verma
    • Ashok Ramnandan Kumar
  • As per Ministry of Corporate Affairs (Mca), the registered address of Aarvis Novo Private Limited is Fl-201 Sai Sparsh Pl-E-17C Sec-3 Belpada, India, Kharghar, Maharashtra, 410210.

  • The corporate identification number (CIN) of Aarvis Novo Private Limited is U74999MH2018PTC305285 and the company number is 305285 as per Ministry of Corporate Affairs (MCA).

  • The financial reports for the fiscal year 2020 indicates that The net worth of Aarvis Novo Private Limited has experienced an downturn of -22.19%.

  • The most recent Balance Sheet for Aarvis Novo Private Limited was filed with the ROC on 31 Mar 2022.

People also Viewed

Similar Companies Based on Drug Formulation & Development